XASXTRI
Market cap73mUSD
Nov 02, Last price
0.03AUD
Name
Medibio Ltd
Chart & Performance
P/E
—
P/S
5,356.81
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
-35.96%
Revenues
22k
-44.87%
Net income
-3m
L-75.47%
CFO
-932k
L-43.88%
Earnings
Feb 26, 2025
Profile
Medibio Limited, a health technology company, assists in the detection and screening of mental health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as BioProspect Limited and changed its name to Medibio Limited in November 2014. Medibio Limited was incorporated in 1987 and is headquartered in Melbourne, Australia.
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | 2016‑06 | 2015‑06 | |
| Income | |||||||||
Revenues | 22 -44.87% | 40 -60.61% | |||||||
Cost of revenue | 1,139 | 2,233 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (1,117) | (2,193) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | 955 | 976 | |||||||
Tax Rate | |||||||||
NOPAT | (2,072) | (3,170) | |||||||
Net income | (3,120) -75.47% | (12,716) 755.36% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 2,507 | 3,380 | |||||||
BB yield | -2,197.32% | ||||||||
| Debt | |||||||||
Debt current | 104 | 66 | |||||||
Long-term debt | 104 | 66 | |||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | (7) | (900) | |||||||
| Cash flow | |||||||||
Cash from operating activities | (932) | (1,661) | |||||||
CAPEX | (2,259) | (3,110) | |||||||
Cash from investing activities | (2,259) | (3,110) | |||||||
Cash from financing activities | 2,467 | 3,335 | |||||||
FCF | (878) | (3,097) | |||||||
| Balance | |||||||||
Cash | 214 | 1,033 | |||||||
Long term investments | |||||||||
Excess cash | 213 | 1,031 | |||||||
Stockholders' equity | 6,296 | 7,106 | |||||||
Invested Capital | 6,187 | 6,142 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 102,547 | ||||||||
Price | 0.00 -78.57% | ||||||||
Market cap | 154 -70.14% | ||||||||
EV | (746) | ||||||||
EBITDA | (1,117) | (2,193) | |||||||
EV/EBITDA | 0.34 | ||||||||
Interest | 13 | 9 | |||||||
Interest/NOPBT | |||||||||